This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Hepatic disease				
Liver disease	Farnesoid X receptor (FXR; NR1H4); G protein-coupled bile acid receptor 1 (GPBAR1; TGR5)	<p>Mouse studies suggest the FXR and TGR5 dual agonist INT-767 could help treat nonalcoholic fatty liver disease (NAFLD). In a mouse model for obesity-induced NAFLD, INT-767 decreased hepatic steatosis and inflammation compared with no agonist. Next steps could include evaluating INT-767 in additional mouse models of NAFLD.</p> <p>Intercept Pharmaceuticals Inc. has INT-767 in preclinical development to treat renal diseases.</p> <p>SciBX 6(11); doi:10.1038/scibx.2013.266 Published online March 21, 2013</p>	Multiple patents covering FXR agonists filed by Intercept Pharmaceuticals; licensing status unavailable	<p>McMahan, R. <i>et al. J. Biol. Chem.</i>; published online March 4, 2013; doi:10.1074/jbc.M112.446575</p> <p>Contact: Hugo R. Rosen, University of Colorado Denver, Aurora, Colo. e-mail: hugo.rosen@ucdenver.edu</p>